Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[89Zr]Zr-RDT-008
- Development stage
- Preclinical
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
[89Zr]Zr-RDT-008 is a site-specifically radiolabeled anti-CD70 monoclonal antibody developed by the MD Anderson Cancer Center Therapeutics Discovery Division. It consists of the fully human anti-CD70 monoclonal antibody RDT-008 conjugated to the chelator maleimide-desferrioxamine (maleimide-DFO) using THIOMAB technology, and radiolabeled with the positron-emitting isotope zirconium-89 (89Zr). [89Zr]Zr-RDT-008 is designed as an immuno-PET imaging agent for the non-invasive detection and monitoring of CD70 expression in clear cell renal cell carcinoma (ccRCC) and other CD70-positive solid tumors. Preclinical studies have demonstrated high target specificity, rapid internalization, and excellent tumor-to-background contrast in ccRCC models, suggesting its potential as a companion diagnostic for CD70-targeted therapies.
- Other names
- 89Zr-RDT-008
02
Targets
CD70 (Cluster of Differentiation 70)
Beyond the preview
Go deeper on [89Zr]Zr-RDT-008.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [89Zr]Zr-RDT-008.